Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
APTO 
Aptose Biosciences Inc (APTO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/07/2025: APTO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -46.28% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/07/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.58M USD | Price to earnings Ratio - | 1Y Target Price 12.5 |
Price to earnings Ratio - | 1Y Target Price 12.5 | ||
Volume (30-day avg) 415836 | Beta 1.13 | 52 Weeks Range 1.35 - 47.40 | Updated Date 04/1/2025 |
52 Weeks Range 1.35 - 47.40 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -87.6 |
Earnings Date
Report Date 2025-03-24 | When After Market | Estimate -6.775 | Actual -34.9 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -142.26% | Return on Equity (TTM) -694.13% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 579682 | Price to Sales(TTM) - |
Enterprise Value 579682 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.05 | Shares Outstanding 2552430 | Shares Floating 499774 |
Shares Outstanding 2552430 | Shares Floating 499774 | ||
Percent Insiders 24.8 | Percent Institutions 11.51 |
Analyst Ratings
Rating 4 | Target Price 2 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Aptose Biosciences Inc
Company Overview
History and Background
Aptose Biosciences Inc. is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in life-threatening cancers. Founded in 2005, the company has focused on developing small molecule kinase inhibitors.
Core Business Areas
- Hematologic Oncology: Aptose focuses on developing therapies for hematologic malignancies, including acute myeloid leukemia (AML) and other blood cancers.
Leadership and Structure
William G. Rice is the Chairman, President, and CEO. The company has a typical organizational structure for a biotech firm, including research and development, clinical operations, and business development departments.
Top Products and Market Share
Key Offerings
- Tuspetinib (CG-806): An oral, first-in-class mutation-agnostic kinase inhibitor in Phase 3 clinical development for relapsed or refractory acute myeloid leukemia (AML). No current market share as it is an investigational agent. Competitors include approved therapies such as venetoclax and azacitidine, as well as other investigational agents in development.
- Luxeptinib (CG-767): An investigational oral kinase inhibitor. Currently undergoing Phase 1 clinical trials. No current market share. Competitors include drugs targeting kinases relevant in various cancers.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high research and development costs, long regulatory approval timelines, and intense competition. The oncology segment is particularly active, with numerous companies developing novel therapies.
Positioning
Aptose Biosciences is positioned as a company developing novel kinase inhibitors for hematologic malignancies, particularly AML. Its competitive advantage lies in its first-in-class Tuspetinib.
Total Addressable Market (TAM)
The global AML market is projected to reach billions of dollars. Aptose is positioned to capture a portion of this market with successful clinical development and commercialization of Tuspetinib.
Upturn SWOT Analysis
Strengths
- Novel kinase inhibitor platform
- Potential first-in-class drug (Tuspetinib)
- Experienced management team
- Clinical-stage pipeline
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Competition from established pharmaceutical companies
- Drug approval regulatory hurdles
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into other indications
- Fast track designation or breakthrough therapy designation from regulatory agencies
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from other emerging therapies
- Patent challenges
Competitors and Market Share
Key Competitors
- VRTX
- MRTX
- AZN
Competitive Landscape
Aptose faces significant competition from established pharmaceutical companies with greater resources and marketing capabilities. Its success hinges on the differentiation and efficacy of its novel kinase inhibitors.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by progress in clinical trials and financings.
Future Projections: Future growth depends on successful clinical development and commercialization of Tuspetinib and other pipeline assets. Analyst estimates can be found on financial websites.
Recent Initiatives: Focus on advancing Tuspetinib through Phase 3 clinical trial.
Summary
Aptose Biosciences is a clinical-stage biotech company with a focus on hematologic malignancies. Its strength lies in the first-in-class potential of Tuspetinib; however, its reliance on clinical trial success poses a risk. Aptose should continue to seek strategic partnerships to enhance its financial position while navigating the competitive landscape of the pharmaceutical industry, especially watching larger pharmaceuticals developing similar drugs.
Similar Companies
- ARRY
- BLCM
- KPTI
Sources and Disclaimers
Data Sources:
- Aptose Biosciences Inc. SEC Filings, Investor Relations Materials, Third-party market research reports.
- Company's Website
- Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aptose Biosciences Inc
Exchange NASDAQ | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2014-10-23 | Chairman, President & CEO Dr. William G. Rice Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 35 | Website https://www.aptose.com |
Full time employees 35 | Website https://www.aptose.com | ||
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.